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ABSTRACT
The COVID-19 pandemic caused by the SARS- CoV-2 virus 
has resulted in a myriad of interventions with the urgent 
aim of reducing the public health impact of this virus. 
However, a wealth of evidence both from high- income 
and low- income countries is accruing on the broader 
consequences of such interventions on economic and 
public health inequalities, as well as on pre- existing 
programmes targeting endemic pathogens. We provide an 
overview of the impact of the ongoing COVID-19 pandemic 
on hepatitis B virus (HBV) programmes globally, focusing 
on the possible consequences for prevention, diagnosis 
and treatment. Ongoing disruptions to infrastructure, 
supply chains, services and interventions for HBV are likely 
to contribute disproportionately to the short- term incidence 
of chronic hepatitis B, providing a long- term source of 
onward transmission to future generations that threatens 
progress towards the 2030 elimination goals.
BACKGROUND
The COVID-19 pandemic, which by October 
2020 had caused more than a million deaths 
worldwide,1 has exposed fault- lines and vulner-
abilities in global health systems. The human 
and economic costs of the pandemic extend far 
beyond the direct impact of SARS- CoV-2 infec-
tion, including death and illness due to health 
system disruptions, as well as unemployment 
and poverty at a massive scale. We here consider 
the impact of the COVID-19 pandemic on hepa-
titis B virus (HBV), a blood- borne virus that 
accounts for a large global burden of chronic 
liver disease, resulting in over one million 
deaths every year from liver cancer and liver 
cirrhosis,2 3 despite the availability of an effective 
vaccine and suppressive antiviral treatment.
HBV is highly endemic in some of the world’s 
poorest populations with limited healthcare 
infrastructure, particularly in sub- Saharan 
Africa and Asia Pacific.4 Just 20 countries 
account for over 75% of the global burden of 
HBV.3 It is estimated that between 1990 and 
2020, childhood vaccination campaigns have 
prevented 310 million new HBV infections,3 
but other high risk groups remain vulner-
able to infection, including people who inject 
drugs and men who have sex with men.3 The 
Sustainable Development Goals set ambi-
tious targets, aiming to eliminate HBV infec-
tion as a public health problem by 2030. A 
multi- pronged approach will be needed to 
deliver these aims,2 including the prevention 
of vertical transmission and universal access 
to testing and treatment services. Evidence 
of the effect of the COVID-19 pandemic on 
the estimated 290 million people living with 
Summary box
 ► The maintenance of programmes to tackle hepatitis 
B virus (HBV) is fragile, particularly in low- income 
and middle- income countries, as funding is fre-
quently not embedded in domestic budgets and 
programmes are often not supported by national 
strategic plans.
 ► The most vulnerable members of society are more 
likely to be affected by HBV, and the COVID-19 pan-
demic is amplifying pre- existing economic and pub-
lic health inequalities.
 ► Historical data clearly illustrate the disruptive legacy 
of political and economic crises on HBV vaccination 
programmes. Evidence is slowly emerging on the 
greater health impacts of COVID-19 public health 
interventions on current HBV initiatives, both in high- 
income and low- income countries, with disruptions 
to infrastructure, services and supply chains for di-
agnosis, vaccination and treatment recorded.
 ► Ongoing short- term disruptions to HBV programmes 
can have strong repercussions on early childhood 
incidence, fuelling an increase in the global burden 
of chronic infection in the long term and providing a 
source of onward transmission to future generations 
that threatens progress towards the 2030 elimina-
tion goals.  on A
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chronic HBV (CHB) worldwide has progressively accrued 
from primary research studies using physician surveys 
and routine health system data, with reports that approxi-
mately 90% of viral hepatitis services have been disrupted 
during the COVID-19 pandemic.5 6 Major global public 
health interventions will remain essential to curtailing 
the pandemic, but awareness of broader consequences is 
crucial. This article provides an evidence synthesis of the 
pandemic’s global impact on HBV prevention, diagnosis 
and treatment, and suggestions for domains where action 
is needed to address specific challenges.
DISRUPTED VACCINATION CAMPAIGNS
There is previous evidence to show that routine immuni-
sation programmes are highly vulnerable to disruption 
resulting from epidemics, political upheaval or economic 
crises. When vaccination coverage rates sharply dipped 
in West Africa during the 2013–2016 Ebola outbreak, 
the incidence of measles rapidly rebounded.7 Although 
HBV global vaccination coverage has steadily increased 
since the 1990s, previous experience shows correlation 
of declines in vaccination coverage with political and 
economic unrest that disrupt infrastructure (figure 1). 
Since the progression to overt liver disease occurs slowly, 
the impact of a drop in HBV vaccination coverage may 
go unnoticed for decades in settings without adequate 
diagnostic infrastructure.
Preliminary data from the Institute for Health Metrics 
and Evaluation indicate that overall global vaccination 
coverage levels in 2020 have dropped to levels last seen 
in the 1990s, threatening 25 years of progress in just 6 
months.8 The USA’s federally financed ‘Vaccines for Chil-
dren’ Programme has documented notable declines in 
vaccine ordering and administration after declaration 
of the national emergency on 13 March 2020, although 
more markedly in children older than 24 months than 
younger children, reflecting some success in maintaining 
routine vaccination of infants.9 In England, electronic 
health records have shown that coverage of the measles, 
mumps, rubella vaccination dropped by 19.8% when 
physical distancing measures were implemented between 
February and April 2020, compared with the same period 
in 2019.10
Reduced vaccination coverage may have particularly 
strong repercussions on HBV incidence in infancy and 
early childhood, contributing to an increase in the global 
burden of chronic infection and providing a long- term 
source of onward transmission that threatens prog-
ress towards the 2030 elimination goals. The repercus-
sions of the COVID-19 pandemic on HBV vaccination 
and control may even outweigh the number of direct 
COVID-19 deaths in the long term. A recent model has 
projected that for one excess COVID-19 death attribut-
able to visiting a vaccination delivery point, mostly in 
the older household contacts of children, the deaths of 
84 children under 5 years could be prevented if routine 
childhood immunisation programmes were sustained in 
sub- Saharan Africa.11
Sustaining HBV vaccination is further complicated 
by pandemic- driven bottlenecks in the supply chain of 
vaccines, increases in home births hindering administra-
tion of birth dose vaccine, changes in healthcare seeking 
behaviour and potential effects on vaccine hesitancy.12 
Vaccination acceptance is closely linked to fear of the 
related disease and trust in government agencies.13 Both 
of these factors are labile due to COVID-19. While risk 
Figure 1 Hepatitis B vaccination coverage annotated to show correlation with societal disruption. Panels show the temporal 
correlation of drops in vaccination coverage with national crises (white line), such as the transfer of presidential duties in Cuba 
(2006–2008), the civil war in Libya (2014–present), a period of social unrest in Georgia (2009), a recent Ivorian political crisis 
(2010–2011), the civil war in Syria (2011–present) and the period of military- enforced political reforms in Myanmar (2011–2015). 
Data source: WHO/UNICEF (apps.who.int/immunization_monitoring/globalsummary).
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perception of the danger of infectious diseases may have 
increased, the politicisation of the pandemic has also 
caused a surge in anti- science sentiment and government 
distrust across the globe.
ALTERED TRANSMISSION DYNAMICS
Evidence on the effect of the pandemic on the trans-
mission of HBV is limited. While transmission may have 
decreased due to physical contact and movement restric-
tions imposed in many countries, these exceptional 
circumstances may have also led to an increase in risk 
behaviours for HBV transmission, including alcohol and 
drug use, unprotected sex, reduced anti- viral treatment 
availability and increased home births.12 Disruption of 
harm reduction services, such as needle exchange and 
opioid substitution therapy, which are already scarce in 
many low- income and middle- income countries (LMICs), 
not only jeopardises the health of people who inject drugs 
and increases the risk of overdoses, but also increases 
the risk of transmission of blood- borne viral infections. 
COVID-19 restrictions leading to temporary closures of 
health centres offering harm reduction services have 
been reported from South Africa,14 and although data 
in other LMICs are lacking, similar events are likely to be 
widespread.
Vertical transmission may also increase as antenatal 
care services are disrupted and more women give birth 
at home, risking an increased burden of CHB among 
infants born during the pandemic. Reduced access to 
interventions for prevention of mother to child trans-
mission (PMTCT) (including antenatal diagnostics, anti-
viral therapy, hepatitis B immunoglobulin and vaccine 
birth doses) endangers a generation of individuals, who 
are more likely to develop chronic infection following 
exposure early in life. In the long term, such temporary 
increases in HBV chronic prevalence in the young can 
contribute to a positive feedback loop of transmission to 
subsequent generations.
DECREASED DIAGNOSTIC CAPACITY
Even before COVID-19, only approximately 1% of viral 
hepatitis cases were diagnosed in sub- Saharan Africa.12 
Therefore, although the pandemic may further exac-
erbate difficulties in identifying infections, in some 
parts of the world, the impact of disrupted vaccination 
campaigns, PMTCT programmes and antiviral treat-
ment on the HBV epidemic will likely be greater than 
reduced diagnostic capacity. Nonetheless, missed diag-
noses prevent entry into care and can have a long- term 
impact on transmission dynamics. Access to healthcare, 
including testing and screening programmes, has been 
affected by the diversion of funding, human resources 
and infrastructure to the COVID-19 response, as well as 
reduced demand as a result of movement restrictions and 
fear of contracting COVID-19 in healthcare settings.1 In 
sub- Saharan Africa, a decrease in new HBV diagnoses was 
observed even before the first local COVID-19 cases were 
reported, suggesting an early influence of outbreaks in 
other countries.4 In April, health centres in Burkina Faso, 
the Gambia and Tanzania recorded significant declines 
in new patients reviewed in outpatient clinics compared 
with the start of the year, falling by 71%, 83% and 95% 
respectively, with the primary reason cited as patients’ fear 
of entering health services.4 Disruptions in global supply 
chains, particularly early on in the pandemic, affected 
the availability of diagnostic platforms and reagents, and 
shortages of nucleic acid tests for HBV DNA testing were 
reported from sub- Saharan Africa.4
REDUCED ACCESS TO TREATMENT
Clinical guidelines recommend that HBV therapy should 
be initiated and continued regardless of COVID-19 
status.15 However, access to healthcare has been 
constrained for HBV- positive individuals as a result of a 
myriad of interdependent factors, including redirected 
finances, redeployment of health workers, closure of 
facilities, supply chain disruptions, movement restric-
tions, fear of entering health facilities and the imprac-
ticality of telemedicine in many settings.12 At the height 
of Italy’s first wave, one in four hepatology wards had 
been converted into COVID-19 wards and the services 
of one in four outpatient hepatology clinics had been 
completely interrupted.16 The degree of disruption in 
Italy was negatively correlated with the severity of HBV- 
associated disease, but nevertheless only 18% of patients 
with hepatocellular carcinoma and 32% of patients with 
decompensated cirrhosis experienced continuity of 
service delivery.16 The initiation of drug treatment for 
HBV was also postponed in 23% of centres in Italy.16 
Reduced demand for healthcare has been reported 
from LMICs as well as high- income countries (HICs).4 
In Japan, Singapore and the USA, consultations for CHB 
decreased significantly compared with 2019, with the 
largest drop in adults older than 65 years.17
In a survey conducted by the World Hepatitis Alliance, 
52% of frontline health workers in LMICs reported that 
patients on treatment for viral hepatitis were unable to 
access medication.6 The primary reasons cited by the 
respondents were patient anxiety surrounding health 
facilities, national stay- at- home orders and insufficient 
financial resources to purchase medicines out- of- pocket as 
pandemic job losses impact household incomes.6 Barriers 
to accessing HBV treatment were further compounded 
by supply chain disruptions of antiviral drugs in both the 
public and private sectors in sub- Saharan Africa.12 Inter-
rupted, prematurely terminated or substandard treat-
ments increase the risk of disease flare with public health 
consequences, including increased transmission risk and 
the threat of drug resistance emergence.
While emerging evidence suggests a link between 
cirrhosis and end- stage liver disease and the risk of severe 
COVID-19,18 19 the control of HBV is further complicated 
by the small risk of reactivation of dormant infection 
following treatment with tocilizumab and corticosteroids 
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for COVID-19.15 20 This risk may be lowered with short 
courses of antiviral prophylaxis alongside COVID-19 
medications in patients with comorbid CHB, however, 
this approach would require the necessary healthcare 
infrastructure to maintain diagnostic and treatment 
services.15 20
HEALTH INEQUALITIES
The COVID-19 pandemic is amplifying existing economic 
and public health inequalities. The pandemic is likely 
to cause a worldwide recession and the contraction of 
national economies, pushing millions more below the 
poverty line, especially in countries without universally 
accessible health systems and already high levels of out- 
of- pocket spending on health.21 Furthermore, the most 
vulnerable members of society are not only more likely 
to be affected by HBV, but they are also more likely to 
have comorbid non- communicable diseases that raise 
the risk of a severe COVID-19 disease course. Rural and 
indigenous communities in LMICs, as reported in India 
Figure 2 Top panel: summary of the possible impact of the COVID-19 pandemic on HBV vaccination, transmission, diagnosis 
and treatment. Overarching factors, including the availability of funding and the ability to conduct advocacy, research, 
health education and community engagement, affect all levels of HBV control. Bottom panel: table of recommendations for 
policymakers and for further research to better understand and mitigate the impact of COVID-19 on HBV prevention, diagnosis 
and treatment. HBV, hepatitis B virus.
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and Nigeria, are most severely affected by movement 
restrictions, as they impede access to health centres and 
the ability to earn a living wage.6 Individuals working 
in unstable employment arrangements risk losing their 
health insurance, and those working in the informal 
sector frequently already pay for healthcare expenditures 
out- of- pocket, with no access to fiscal stimulus packages 
and other social safety nets if they lose their employment. 
Such issues extend to HICs, such as the USA, where a large 
number of job losses have led to 6.2 million people losing 
their health insurance since the onset of the COVID-19 
pandemic.22 Drops in healthcare coverage will likely lead 
to worsening of chronic conditions, including CHB, and 
may reduce the incentive to seek testing services when 
treatment is unaffordable.
CONCLUSION
Beyond prevention, diagnosis and treatment (figure 2), 
the impact of COVID-19 on the global health architecture 
and development assistance programmes may also have 
far- reaching effects on global efforts to control HBV. The 
maintenance of viral hepatitis programmes is fragile, as 
funding is frequently not embedded in domestic budgets 
and programmes are often not supported by national stra-
tegic plans. The diversion of funding is also impeding the 
ability of civil society to continue their advocacy activities 
and engage in health education activities in communities 
affected by hepatitis. Disruption of HBV prevention, diag-
nosis and treatment services threatens to derail progress 
made so far on reducing the global burden of HBV, and 
pushes the 2030 goal of elimination further out of reach. 
Building on the findings of this study and the WHO pulse 
survey on continuity of essential health services during 
the COVID-19 pandemic,23 we provide a non- exhaustive 
suite of recommendations (figure 2) for policymakers and 
researchers to better understand and mitigate the impact 
of the COVID-19 pandemic on HBV prevention, diagnosis 
and treatment.
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